Abstract
Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 236-241 |
| Number of pages | 6 |
| Journal | Clinical Infectious Diseases |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jul 15 2008 |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
Maraviroc : The first of a new class of antiretroviral agents. / MacArthur, Rodger D.; Novak, Richard M.
In: Clinical Infectious Diseases, Vol. 47, No. 2, 15.07.2008, p. 236-241.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Maraviroc
T2 - The first of a new class of antiretroviral agents
AU - MacArthur, Rodger D.
AU - Novak, Richard M.
PY - 2008/7/15
Y1 - 2008/7/15
N2 - Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.
AB - Maraviroc is the first US Food and Drug Administration-approved drug from a new class of antiretroviral agents that targets a host protein, the chemokine receptor CCR5, rather than a viral target. Binding of maraviroc to this cell-surface protein results in blocking human immunodeficiency virus type 1 (HIV-1) attachment to the coreceptor and prevents the virus from entering CD4+ cells. In this review, we include the details of the discoveries that led to the development of this drug. The drug's pharmacology, including pharmacokinetics and drug interactions, is discussed, as are the clinical efficacy studies that led to licensure. HIV-1 mechanisms of resistance to maraviroc, assays to determine viral coreceptor use (tropism), drug safety, and clinical use of maraviroc are discussed at length.
UR - http://www.scopus.com/inward/record.url?scp=46349097362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46349097362&partnerID=8YFLogxK
U2 - 10.1086/589289
DO - 10.1086/589289
M3 - Review article
C2 - 18532888
AN - SCOPUS:46349097362
VL - 47
SP - 236
EP - 241
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 2
ER -